PL3429580T3 - Kompozycja kannabinoidowa wzbogacona terpenami - Google Patents
Kompozycja kannabinoidowa wzbogacona terpenamiInfo
- Publication number
- PL3429580T3 PL3429580T3 PL17765961.2T PL17765961T PL3429580T3 PL 3429580 T3 PL3429580 T3 PL 3429580T3 PL 17765961 T PL17765961 T PL 17765961T PL 3429580 T3 PL3429580 T3 PL 3429580T3
- Authority
- PL
- Poland
- Prior art keywords
- terpenes
- composition enriched
- cannabinoid composition
- cannabinoid
- enriched
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308961P | 2016-03-16 | 2016-03-16 | |
| PCT/IB2017/051515 WO2017158539A1 (en) | 2016-03-16 | 2017-03-15 | Terpene-enriched cannabinoid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3429580T3 true PL3429580T3 (pl) | 2025-09-22 |
Family
ID=59851061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17765961.2T PL3429580T3 (pl) | 2016-03-16 | 2017-03-15 | Kompozycja kannabinoidowa wzbogacona terpenami |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180169035A1 (pl) |
| EP (2) | EP3429580B1 (pl) |
| CA (2) | CA3283924A1 (pl) |
| ES (1) | ES3037742T3 (pl) |
| IL (3) | IL301006A (pl) |
| PL (1) | PL3429580T3 (pl) |
| PT (1) | PT3429580T (pl) |
| WO (1) | WO2017158539A1 (pl) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11596174B2 (en) | 2015-10-06 | 2023-03-07 | Gseh Holistic, Inc. | Phyto material tablet, method and apparatus |
| AU2017260706B2 (en) | 2016-05-04 | 2023-05-11 | Inmed Pharmaceuticals Inc. | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders |
| JP2019523282A (ja) * | 2016-08-03 | 2019-08-22 | ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド | 大麻組成物 |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3558278B1 (en) * | 2016-12-22 | 2021-07-14 | NordicCan A/S | Liquid cannabinoid composition |
| JP2020520966A (ja) * | 2017-05-22 | 2020-07-16 | ジービーエス グローバル バイオファーマ，インコーポレイテッド | Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物 |
| EP3644976A4 (en) * | 2017-06-28 | 2021-03-24 | Buzzelet Development And Technologies Ltd | TERPEN-ENRICHED CANNABINOID PRODUCT FOR WOMEN'S HEALTH |
| EP3644975A1 (en) * | 2017-06-29 | 2020-05-06 | Canna Therapeutic ApS | A composition comprising a scent for use as a substance dependency rehabilitation composition |
| WO2019056123A1 (en) * | 2017-09-22 | 2019-03-28 | Inmed Pharmaceuticals Inc. | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN |
| WO2019056128A1 (en) * | 2017-09-25 | 2019-03-28 | Canopy Health Innovations | COMPOSITIONS COMPRISING CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENES AND FLAVONOIDS AND THEIR USE IN THE TREATMENT OF INSOMNIA |
| HUE058102T2 (hu) | 2017-09-28 | 2022-07-28 | Zynerba Pharmaceuticals Inc | Fragilis X szindróma és autizmus kezelése kannabidiollal |
| EP3704263A4 (en) | 2017-10-30 | 2021-08-25 | Endocanna Health, Inc. | GRAPHIC USER INTERFACES FOR DETERMINING CUSTOMIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| US11684604B2 (en) | 2018-02-23 | 2023-06-27 | Yuzu Lv Llc | Cannabis based therapeutic and method of use |
| WO2019198056A1 (en) * | 2018-04-14 | 2019-10-17 | Buzzelet Development And Technologies Ltd | Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event |
| EP3793542A4 (en) * | 2018-05-14 | 2022-03-30 | Buzzelet Development And Technologies Ltd | TERPENE-ENRICHED CANNABINOID COMPOSITIONS AND THEIR USES IN THE TREATMENT OF INFECTIOUS DISEASES |
| AU2019272849A1 (en) * | 2018-05-22 | 2021-01-14 | Gbs Global Biopharma, Inc. | Cannabinoids and/or terpenes for use in TRPV1 modulation |
| AU2018100924A4 (en) * | 2018-07-03 | 2018-08-09 | Zelira Therapeutics Operations Pty Ltd | Composition and method for treating pain |
| AU2018100925A4 (en) * | 2018-07-03 | 2018-08-09 | Zelira Therapeutics Operations Pty Ltd | Cannabinoid composition and method for treating PTSD and/or anxiety |
| WO2020012315A1 (en) | 2018-07-08 | 2020-01-16 | Buzzelet Development And Technologies Ltd. | Terpene-enriched cannabinoid composition for treatment of male subjects |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020093170A1 (en) * | 2018-11-09 | 2020-05-14 | Cronos Group Inc. | Liquid composition for an electronic vapor device |
| CA3122735A1 (en) | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| US10959961B2 (en) * | 2018-12-14 | 2021-03-30 | Natural Extraction Systems, LLC | Methods of administering anionic cannabinoid molecules dissolved in water |
| BR112021011509A2 (pt) | 2018-12-14 | 2021-08-31 | Natural Extraction Systems, LLC | Composições e métodos relativos a moléculas de canabinoide aniônicas |
| US10609944B1 (en) | 2018-12-14 | 2020-04-07 | Natural Extraction Systems, LLC | Compositions comprising 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol |
| AU2019412825A1 (en) * | 2018-12-27 | 2021-08-12 | Buzzelet Development And Technologies Ltd. | Herbal preparation-enriched cannabinoid composition and method of treatment |
| EP3902538A4 (en) * | 2018-12-29 | 2023-01-18 | Buzzelet Development And Technologies Ltd | ISOLATED OR SYNTHETIC CANNABINOID COMPOSITIONS WITH SELECTED TERPEN BLEND AND METHODS OF USE THEREOF |
| AU2020215164B2 (en) * | 2019-01-29 | 2025-04-03 | Buzzelet Development And Technologies Ltd. | Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder |
| US20220151978A1 (en) * | 2019-02-17 | 2022-05-19 | Buzzelet Development And Technologies Ltd. | A kit for treating pelvic pain arising from female reproductive system |
| AU2020232029B2 (en) * | 2019-03-07 | 2024-03-14 | Ilera Therapeutics Llc | Formulations for treating cluster symptoms associated with autism spectrum disorder |
| IL286273B2 (en) * | 2019-03-24 | 2025-11-01 | Buzzelet Development And Technologies Ltd | Cannabis inhalation products and methods of production thereof |
| US10993928B2 (en) | 2019-04-26 | 2021-05-04 | Natural Extraction Systems, LLC | Compositions comprising non-crystalline forms of cannabidiol |
| WO2020219829A1 (en) * | 2019-04-26 | 2020-10-29 | Natural Extraction Systems, LLC | Compositions comprising non-crystalline forms of cannabidiol |
| US20220233463A1 (en) * | 2019-05-16 | 2022-07-28 | Buzzelet Development And Technologies Ltd. | Local anesthetic comprising a trp channel modulator |
| WO2020234650A1 (en) * | 2019-05-21 | 2020-11-26 | Timeless Herbal Care (Canada) Ltd. | Pharmaceutical compositions comprising cbd and terpene compositions |
| WO2021033149A1 (en) * | 2019-08-19 | 2021-02-25 | Buzzelet Development And Technologies Ltd. | Compositons for the treatment of a condition characterized by anandamide deficiency and uses thereof |
| WO2021046422A2 (en) | 2019-09-06 | 2021-03-11 | Perfect Herbal Blends, Inc. | Optimizing volatile entourages in dry flowering plant mixtures |
| CA3156257A1 (en) | 2019-10-03 | 2021-04-08 | Starton Therapeutics, Inc. | TRANSDERMAL DELIVERY OF DRONABINOL |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| MX2022004258A (es) | 2019-10-14 | 2022-05-26 | Pike Therapeutics Inc | Entrega transdermica de cannabidiol. |
| EP4081208A4 (en) * | 2019-12-28 | 2024-01-03 | Buzzelet Development And Technologies Ltd | LIQUID COMPOSITIONS INCLUDING TERPENES AND CANNABINOIDS |
| WO2021151212A1 (en) * | 2020-01-31 | 2021-08-05 | Hexo Operations Inc. | System and method for quantifying, formulating and enhancing user experience profile of cannabis |
| AU2021279461A1 (en) * | 2020-05-24 | 2023-02-02 | Asana Bio Group Ltd. | Compositions of cannabinoids and methods of using same |
| US20230270764A1 (en) * | 2020-07-14 | 2023-08-31 | Raz Yirmiya | Composition comprising cannabinoids, terpenes, and flavonoids for treating depression |
| IT202000017137A1 (it) * | 2020-07-15 | 2022-01-15 | Linnea Sa | Estratti di cannabis sativa e loro usi |
| WO2022026960A1 (en) | 2020-07-31 | 2022-02-03 | Natural Extraction Systems, LLC | Compositions and methods related to excipients and cannabinoid formulations |
| EP4203947A4 (en) * | 2020-08-27 | 2025-01-22 | Credo Science, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS |
| EP4232017A4 (en) * | 2020-10-21 | 2024-09-04 | Inmed Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS USING CANNABINOIDS |
| WO2022112511A1 (en) * | 2020-11-26 | 2022-06-02 | Alain Moussy | Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area |
| EP4255404A4 (en) * | 2020-12-04 | 2025-02-26 | Cymra Life Sciences Limited | ANTI-INFLAMMATORY COMPOSITIONS WITH CANNABIDIOL, DELTA-9-TETRAHYDROCANNABINOL AND LINALOOL |
| US20240366634A1 (en) * | 2021-09-03 | 2024-11-07 | Buzzelet Development And Technologies Ltd. | Methods for the treatment of cb1-, trpa1- and trpv1-dependent conditions |
| WO2023126934A1 (en) * | 2021-12-29 | 2023-07-06 | Canonic Ltd. | Cannabis compositions for treating pain and inflammation related disorders |
| CA3254374A1 (en) * | 2022-05-16 | 2023-11-23 | Buzzelet Development And Technologies Ltd. | COMPOSITIONS CONTAINING TERPENES |
| WO2025090587A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Cannabinoids compounds and their use in the treatment of neuronal disorders |
| GB202316857D0 (en) * | 2023-11-03 | 2023-12-20 | Mrx Medical Ltd | Cannabinoid-based formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313106B1 (en) * | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| US20080112895A1 (en) * | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| GB2491380A (en) * | 2011-06-01 | 2012-12-05 | Jagotec Ag | Pharmaceutical composition comprising dronedarone hydrochloride that exhibits a reduced food effect |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US20150313868A1 (en) * | 2012-12-18 | 2015-11-05 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| EP2968259B1 (en) * | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioactive concentrates and uses thereof |
| CA2911168C (en) * | 2013-10-29 | 2018-08-14 | Biotech Institute, Llc | Production and use of specialty cannabis with bd/bt genotype and a beta caryophyllene-dominant terpene profile |
| WO2015068052A2 (en) * | 2013-10-31 | 2015-05-14 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
| US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US20160039591A1 (en) * | 2014-07-22 | 2016-02-11 | Craig E. Kinzer | Packaging systems, devices, methods, and composition including cannabinoid unit dose forms |
| US11793769B2 (en) * | 2014-08-25 | 2023-10-24 | Jai Shankar Sukul | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| MA40910A (fr) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
-
2017
- 2017-03-15 PT PT177659612T patent/PT3429580T/pt unknown
- 2017-03-15 EP EP17765961.2A patent/EP3429580B1/en active Active
- 2017-03-15 CA CA3283924A patent/CA3283924A1/en active Pending
- 2017-03-15 WO PCT/IB2017/051515 patent/WO2017158539A1/en not_active Ceased
- 2017-03-15 ES ES17765961T patent/ES3037742T3/es active Active
- 2017-03-15 IL IL301006A patent/IL301006A/en unknown
- 2017-03-15 US US15/578,882 patent/US20180169035A1/en not_active Abandoned
- 2017-03-15 EP EP25165017.2A patent/EP4552652A3/en active Pending
- 2017-03-15 PL PL17765961.2T patent/PL3429580T3/pl unknown
- 2017-03-15 IL IL307857A patent/IL307857A/en unknown
- 2017-03-15 CA CA3017696A patent/CA3017696C/en active Active
-
2018
- 2018-09-05 IL IL261629A patent/IL261629B2/en unknown
-
2022
- 2022-05-02 US US17/734,132 patent/US20220323371A1/en not_active Abandoned
-
2023
- 2023-10-17 US US18/380,680 patent/US20240099987A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL261629B2 (en) | 2023-08-01 |
| WO2017158539A1 (en) | 2017-09-21 |
| IL261629B1 (en) | 2023-04-01 |
| EP4552652A3 (en) | 2025-09-17 |
| EP4552652A2 (en) | 2025-05-14 |
| US20240099987A1 (en) | 2024-03-28 |
| ES3037742T3 (en) | 2025-10-06 |
| IL301006A (en) | 2023-04-01 |
| US20180169035A1 (en) | 2018-06-21 |
| IL261629A (en) | 2018-10-31 |
| EP3429580A1 (en) | 2019-01-23 |
| CA3017696C (en) | 2025-11-18 |
| CA3283924A1 (en) | 2025-11-29 |
| PT3429580T (pt) | 2025-08-12 |
| EP3429580B1 (en) | 2025-05-07 |
| IL307857A (en) | 2023-12-01 |
| EP3429580A4 (en) | 2019-11-13 |
| US20220323371A1 (en) | 2022-10-13 |
| CA3017696A1 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3429580T3 (pl) | Kompozycja kannabinoidowa wzbogacona terpenami | |
| TWI800019B (zh) | 樹脂組成物 | |
| EP3493800A4 (en) | CANNABIS | |
| EP3388403A4 (en) | LAMINATED GLASS | |
| MA46879A (fr) | Composite souple | |
| EP3339331A4 (en) | COMPOSITION | |
| EP3398996A4 (en) | COMPOSITION | |
| DK3558278T3 (da) | Flydende cannabinoidsammensætning | |
| EP3385237A4 (en) | Laminated glass | |
| DK3528902T3 (da) | Ringegelsammensætning | |
| EP3466898A4 (en) | Laminated glass | |
| EP3564321A4 (en) | RESIN COMPOSITION | |
| EP3395887C0 (en) | FLUOROR RUBBER COMPOSITION | |
| DK3322295T3 (da) | Sammensætning | |
| EP3480228A4 (en) | COMPOSITION | |
| EP3595691A4 (en) | PLANT-BASED COMPOSITION | |
| TWI799393B (zh) | 樹脂組成物 | |
| EP3715422A4 (en) | RESIN COMPOSITION | |
| EP3683046A4 (en) | COMPOSITE | |
| EP3556804A4 (en) | COMPOSITION | |
| EP3514221A4 (en) | AROMATIC COMPOSITION | |
| DK3393254T3 (da) | Sammensætning | |
| LT3173071T (lt) | Maropitanto kompozicija | |
| EP3369418A4 (en) | COMPOSITION | |
| EP3600731C0 (de) | Verbundbauteil |